Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial
Posted inHematology-Oncology news Oncology

Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial

The E2C2 trial demonstrates that integrating electronic health record (EHR)-facilitated collaborative care with symptom surveillance significantly reduces the burden of anxiety, depression, and fatigue in oncology patients compared to surveillance alone, offering a scalable model for population-level symptom management.
GLIAA Trial Results: Contrast-Enhanced MRI Remains the Gold Standard for Re-irradiation Planning in Recurrent Glioblastoma
Posted innews Oncology Radiology

GLIAA Trial Results: Contrast-Enhanced MRI Remains the Gold Standard for Re-irradiation Planning in Recurrent Glioblastoma

The multicenter GLIAA trial demonstrated that FET-PET-guided target volume delineation for re-irradiation does not provide a progression-free survival benefit over standard contrast-enhanced T1-weighted MRI in patients with recurrent glioblastoma, solidifying MRI's role as the preferred clinical delineation method.
Preoperative Total Diet Replacement Safely Reduces Morbidity Risk and Preserves Muscle Mass in Colorectal Cancer Surgery
Posted inGeneral Surgery news Oncology

Preoperative Total Diet Replacement Safely Reduces Morbidity Risk and Preserves Muscle Mass in Colorectal Cancer Surgery

The CARE feasibility trial demonstrates that a preoperative low-energy total diet replacement program is safe and effective for colorectal cancer patients with excess weight. Significant weight loss was achieved without compromising lean muscle mass, showing potential for reduced postoperative complications and improved recovery.
Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer
Posted innews Oncology Otorhinolaryngology

Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer

A prospective cohort study demonstrates that a structured shared decision-making (SOP) model significantly increases the utilization of multidisciplinary palliative care services for patients with stage IV oral cavity cancer, bridging the gap between curative intent and supportive care.
Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome
Posted inAI Hematology-Oncology news Oncology

Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome

This article explores a landmark mixed-methods study establishing a digital biomarker ontology for the early detection of Cytokine Release Syndrome (CRS). By identifying core physiological markers, researchers aim to transform immunotherapy safety through continuous monitoring and predictive modeling.
Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial
Posted innews Oncology Otorhinolaryngology

Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial

A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a new standard for holistic supportive care during intensive oncology treatments.
Posted inHematology-Oncology news Oncology

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep responses with initial ibrutinib-venetoclax, while sparing early responders from additional toxicity.
Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia
Posted inHematology-Oncology news Oncology

Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia

Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patients with relapsed T-cell acute lymphoblastic leukemia.
Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention
Posted inHematology-Oncology news Oncology

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention

The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high rates of complete response and minimal residual disease negativity.
Trastuzumab Deruxtecan Redefines Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer: Insights from DESTINY-Breast05
Posted innews Oncology

Trastuzumab Deruxtecan Redefines Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer: Insights from DESTINY-Breast05

The DESTINY-Breast05 trial demonstrates that Trastuzumab Deruxtecan significantly improves invasive disease-free survival compared to Trastuzumab Emtansine in patients with residual HER2-positive early breast cancer, establishing a new potential standard of care while highlighting the need for vigilant monitoring of interstitial lung disease.